{"id":22332,"date":"2026-05-20T09:03:00","date_gmt":"2026-05-20T13:03:00","guid":{"rendered":"http:\/\/4bd619bca4.nxcli.io\/?p=22332"},"modified":"2026-04-10T13:19:49","modified_gmt":"2026-04-10T17:19:49","slug":"dupixent-cancer-risk-what-patients-need-to-know-about-ctcl","status":"publish","type":"post","link":"https:\/\/napolilaw.com\/es\/article\/dupixent-cancer-risk-what-patients-need-to-know-about-ctcl\/","title":{"rendered":"Dupixent Cancer Risk: What Patients Need to Know\u00a0About CTCL"},"content":{"rendered":"<p><strong>Emerging Research Raises Questions About Dupixent\u2019s Safety Profile<\/strong>&nbsp;<\/p>\n\n\n\n<p><strong>Dupixent (dupilumab)<\/strong>&nbsp;has become one of the most widely prescribed biologic medications for chronic inflammatory conditions, helping over one million patients worldwide manage diseases like eczema and asthma. Manufactured by Sanofi and Regeneron, the drug is often seen as a breakthrough for individuals struggling with hard-to-treat conditions.&nbsp;<\/p>\n\n\n\n<p>Sin embargo,&nbsp;<strong>recent studies have raised concerns about a&nbsp;possible link&nbsp;between&nbsp;Dupixent&nbsp;and a rare form of cancer known as cutaneous T-cell<\/strong><strong>&nbsp;lymphoma (CTCL)<\/strong>. For patients and families, understanding these risks is critical\u2014especially when evaluating long-term treatment options.&nbsp;<\/p>\n\n\n\n<p><strong>What Is Dupixent and How Does It Work?<\/strong>&nbsp;<\/p>\n\n\n\n<p>Dupixent (dupilumab) has become one of the most widely prescribed&nbsp;<strong>biologic medications<\/strong>&nbsp;for chronic inflammatory conditions, helping over one million patients worldwide manage diseases like eczema and asthma. Manufactured by Sanofi and Regeneron, the drug is often seen as a breakthrough for individuals struggling with hard-to-treat conditions.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Derived from living cells and designed to target specific components of the immune system.&nbsp;<\/p>\n\n\n\n<p>It works by blocking proteins known as&nbsp;<strong>interleukin-4 (IL-4) and interleukin-13 (IL-13)<\/strong>, which play a key role in inflammation. By interrupting these pathways, Dupixent helps reduce symptoms in several chronic conditions.&nbsp;<\/p>\n\n\n\n<p><strong>Conditions Treated with Dupixent<\/strong>&nbsp;<\/p>\n\n\n\n<p>Dupixent is approved to treat or&nbsp;assist&nbsp;in treating:&nbsp;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Moderate-to-severe\u00a0<strong>atopic dermatitis (eczema)<\/strong>\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Asma<\/strong>, including steroid-dependent and eosinophilic asthma\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Chronic rhinosinusitis with nasal polyps<\/strong>\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Eosinophilic esophagitis<\/strong>\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prurigo nodularis<\/strong>\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Chronic spontaneous urticaria<\/strong>\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Bullous pemphigoid<\/strong>\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Chronic obstructive pulmonary disease (COPD)<\/strong>\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n<p>For many patients, Dupixent has provided significant relief where other treatments failed. But like all medications, it carries&nbsp;serious&nbsp;potential risks.&nbsp;<\/p>\n\n\n\n<p><strong>What Is Cutaneous T-Cell Lymphoma (CTCL)?<\/strong>&nbsp;<\/p>\n\n\n\n<p><strong>Cutaneous T-cell lymphoma (CTCL)<\/strong>&nbsp;is a rare type of&nbsp;<strong>no linfoma de Hodgkin<\/strong>&nbsp;that primarily affects the skin. It occurs when certain immune cells (T-cells) become cancerous and accumulate in the skin.&nbsp;<\/p>\n\n\n\n<p><strong>Early Symptoms Often Misdiagnosed as Eczema<\/strong>&nbsp;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Persistent rash or patches that may resemble eczema\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Itching (often severe)\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Thickened plaques or tumors on the skin\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Skin discoloration or scaling\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n<p>Since&nbsp;CTCL can mimic common skin conditions like eczema, it is often&nbsp;<strong>misdiagnosed or diagnosed late<\/strong>, making awareness especially important.&nbsp;<\/p>\n\n\n\n<p><strong>Is There a Link Between Dupixent and&nbsp;CTCL?&#8221;<\/strong>&nbsp;<\/p>\n\n\n\n<p><strong>Key Findings&nbsp;From&nbsp;Recent&nbsp;Studies:<\/strong>&nbsp;<\/p>\n\n\n\n<p>Scientific studies have raised concerns about a potential association between Dupixent and CTCL:&nbsp;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>A study published in the\u00a0<a href=\"https:\/\/www.jaad.org\/article\/S0190-9622%2824%2900566-8\/abstract\" target=\"_blank\" rel=\"noreferrer noopener\"><em>Journal of the American Academy of Dermatology<\/em><\/a>\u00a0found that\u00a0<strong>patients using Dupixent had\u00a0approximately a\u00a0fourfold increased risk of developing CTCL<\/strong>\u00a0compared to those who did not use the drug.\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>A second analysis published in\u00a0<a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/2024\/9924306\" target=\"_blank\" rel=\"noreferrer noopener\"><em>Dermatologic Therapy<\/em><\/a>\u00a0<strong>confirmed an elevated risk<\/strong>, particularly:\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>In patients\u00a0<strong>over age 60<\/strong>\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Within the\u00a0<strong>first year of treatment<\/strong>\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n<p>These findings do&nbsp;<strong>not definitively prove causation<\/strong>, but they highlight a&nbsp;<strong>potential safety signal that requires further investigation<\/strong>.&nbsp;<\/p>\n\n\n\n<p><strong>Adverse Event Reports and FDA Data<\/strong>&nbsp;<\/p>\n\n\n\n<p>De acuerdo con la&nbsp;<a href=\"https:\/\/www.fda.gov\/drugs\/fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>FDA\u2019s Adverse Event Reporting System (FAERS)<\/strong>:<\/a>&nbsp;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>M\u00e1s que\u00a0<strong>87,000 adverse events<\/strong>\u00a0involving Dupixent or dupilumab have been reported in 2025\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Among these reports are cases involving\u00a0<strong>cutaneous T-cell lymphoma (CTCL)<\/strong>\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n<p>It is important to understand that&nbsp;<strong>FAERS data is based on voluntary, self-reported information<\/strong>. While it cannot&nbsp;establish&nbsp;a direct cause-and-effect relationship, it is often used to&nbsp;identify&nbsp;potential safety concerns that&nbsp;warrant&nbsp;further study.&nbsp;<\/p>\n\n\n\n<p><strong>What&nbsp;Symptoms Should You Watch For?<\/strong>&nbsp;<\/p>\n\n\n\n<p>If you or a loved one is taking Dupixent,&nbsp;it\u2019s&nbsp;important to&nbsp;monitor&nbsp;for unusual or persistent skin symptoms, including:&nbsp;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Rashes that\u00a0<strong>do not improve or worsen over time<\/strong>\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Skin patches that\u00a0<strong>change in appearance<\/strong>\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Severe or persistent itching\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>New or unusual skin growths\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n<p>If you experience any of these symptoms, seek evaluation from a qualified medical professional as soon as possible.&nbsp;<\/p>\n\n\n\n<p><strong>Legal Implications: Can You File a Dupixent Lawsuit?<\/strong>&nbsp;<\/p>\n\n\n\n<p>Pharmaceutical companies have a legal obligation to&nbsp;<strong>ensure their products are safe and to adequately warn patients and healthcare providers of potential risks<\/strong>.&nbsp;<\/p>\n\n\n\n<p>If evidence shows that:&nbsp;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The risks of CTCL were\u00a0<strong>not properly\u00a0disclosed<\/strong>, o\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Patients were\u00a0<strong>not adequately warned about potential cancer risks<\/strong>,\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n<p>Then,&nbsp;affected individuals may be entitled to pursue compensation.&nbsp;<\/p>\n\n\n\n<p><strong>Who&nbsp;Qualifies for&nbsp;a Claim?<\/strong>&nbsp;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>You were prescribed Dupixent\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>You were later diagnosed with\u00a0<strong>cutaneous T-cell lymphoma (CTCL)<\/strong>\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>You were not warned about this potential risk\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n<p><strong>Contact Our Attorneys for a Free Case Review<\/strong>&nbsp;<\/p>\n\n\n\n<p>If you or someone you love has been diagnosed with CTCL after using Dupixent, you do not have to navigate this situation alone.&nbsp;<\/p>\n\n\n\n<p>Our experienced product liability attorneys are actively investigating potential claims related to Dupixent and cancer risk. We can help&nbsp;determine&nbsp;whether you may be eligible to pursue compensation for:&nbsp;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Gastos m\u00e9dicos\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Lost income\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Dolor y sufrimiento\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Other damages\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n<p><a href=\"http:\/\/napolilaw.com\/dupixent-lawsuit\/\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>Cont\u00e1ctenos<\/strong><\/a><strong>&nbsp;today&nbsp;for a free, no-obligation consultation.<\/strong>&nbsp;There are no upfront costs, and you pay nothing unless we recover compensation on your behalf.&nbsp;<\/p>","protected":false},"excerpt":{"rendered":"<p>Emerging Research Raises Questions About Dupixent\u2019s Safety Profile&nbsp; Dupixent (dupilumab)&nbsp;has become one of the most widely prescribed biologic medications for chronic inflammatory conditions, helping over one million patients worldwide manage&#8230;<\/p>","protected":false},"author":8,"featured_media":22334,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[776],"tags":[],"class_list":["post-22332","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharmaceutical-litigation"],"acf":[],"page_builder_type":"gutenberg","gutenberg_data":[],"_links":{"self":[{"href":"https:\/\/napolilaw.com\/es\/wp-json\/wp\/v2\/posts\/22332","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/napolilaw.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/napolilaw.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/napolilaw.com\/es\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/napolilaw.com\/es\/wp-json\/wp\/v2\/comments?post=22332"}],"version-history":[{"count":2,"href":"https:\/\/napolilaw.com\/es\/wp-json\/wp\/v2\/posts\/22332\/revisions"}],"predecessor-version":[{"id":22335,"href":"https:\/\/napolilaw.com\/es\/wp-json\/wp\/v2\/posts\/22332\/revisions\/22335"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/napolilaw.com\/es\/wp-json\/wp\/v2\/media\/22334"}],"wp:attachment":[{"href":"https:\/\/napolilaw.com\/es\/wp-json\/wp\/v2\/media?parent=22332"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/napolilaw.com\/es\/wp-json\/wp\/v2\/categories?post=22332"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/napolilaw.com\/es\/wp-json\/wp\/v2\/tags?post=22332"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}